BACKGROUND: There is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis. AIMS: To examine the evidence base for this recommendation. METHOD: Meta-analyses of randomised controlled trials in the early phase of psychosis, looking at long-term discontinuation rates, short-term symptom changes, weight gain and extrapyramidal side-effects. Trials were identified using a combination of electronic (Cochrane Central, EMBASE, MEDLINE and PsycINFO) and manual searches. RESULTS: Fifteen randomised controlled trials with a total of 2522 participants were included. No significant differences between atypical and typical drugs were found for discontinuation rates (odds ratio (OR) = 0.7, 95% CI 0.4 to 1.2) or effect on symptoms (standardised mean difference (SMD) = -0.1, 95% CI -0.2 to 0.02). Participants on atypical antipsychotics gained 2.1 kg (95% CI 0.1 to 4.1) more weight than those on typicals, whereas those on typicals experienced more extrapyramidal side-effects (SMD = -0.4, 95% CI -0.5 to -0.2). CONCLUSIONS: There was no evidence for differences in efficacy between atypical and typical antipsychotics, but there was a clear difference in the side-effect profile.
BACKGROUND: There is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis. AIMS: To examine the evidence base for this recommendation. METHOD: Meta-analyses of randomised controlled trials in the early phase of psychosis, looking at long-term discontinuation rates, short-term symptom changes, weight gain and extrapyramidal side-effects. Trials were identified using a combination of electronic (Cochrane Central, EMBASE, MEDLINE and PsycINFO) and manual searches. RESULTS: Fifteen randomised controlled trials with a total of 2522 participants were included. No significant differences between atypical and typical drugs were found for discontinuation rates (odds ratio (OR) = 0.7, 95% CI 0.4 to 1.2) or effect on symptoms (standardised mean difference (SMD) = -0.1, 95% CI -0.2 to 0.02). Participants on atypical antipsychotics gained 2.1 kg (95% CI 0.1 to 4.1) more weight than those on typicals, whereas those on typicals experienced more extrapyramidal side-effects (SMD = -0.4, 95% CI -0.5 to -0.2). CONCLUSIONS: There was no evidence for differences in efficacy between atypical and typical antipsychotics, but there was a clear difference in the side-effect profile.
Authors: L M Davies; S Lewis; P B Jones; T R E Barnes; F Gaughran; K Hayhurst; A Markwick; H Lloyd Journal: Br J Psychiatry Date: 2007-07 Impact factor: 9.319
Authors: Juan R Bustillo; Laura M Rowland; Rex Jung; William M Brooks; Clifford Qualls; Roger Hammond; Blaine Hart; John Lauriello Journal: Neuropsychopharmacology Date: 2007-12-19 Impact factor: 7.853
Authors: Mario Alvarez-Jiménez; César González-Blanch; Benedicto Crespo-Facorro; Sarah Hetrick; Jose Manuel Rodríguez-Sánchez; Rocio Pérez-Iglesias; Jose Luis Vázquez-Barquero Journal: CNS Drugs Date: 2008 Impact factor: 5.749
Authors: Hans-Jürgen Möller; Michael Riedel; Markus Jäger; Florian Wickelmaier; Wolfgang Maier; Kai-Uwe Kühn; Gerhard Buchkremer; Isabella Heuser; Joachim Klosterkötter; Markus Gastpar; Dieter F Braus; Ralf Schlösser; Frank Schneider; Christian Ohmann; Mathias Riesbeck; Wolfgang Gaebel Journal: Int J Neuropsychopharmacol Date: 2008-05-09 Impact factor: 5.176
Authors: René S Kahn; W Wolfgang Fleischhacker; Han Boter; Michael Davidson; Yvonne Vergouwe; Ireneus P M Keet; Mihai D Gheorghe; Janusz K Rybakowski; Silvana Galderisi; Jan Libiger; Martina Hummer; Sonia Dollfus; Juan J López-Ibor; Luchezar G Hranov; Wolfgang Gaebel; Joseph Peuskens; Nils Lindefors; Anita Riecher-Rössler; Diederick E Grobbee Journal: Lancet Date: 2008-03-29 Impact factor: 79.321
Authors: Rocio Perez-Iglesias; Benedicto Crespo-Facorro; Obdulia Martinez-Garcia; Maria L Ramirez-Bonilla; Mario Alvarez-Jimenez; Jose M Pelayo-Teran; Maria T Garcia-Unzueta; Jose A Amado; Jose L Vazquez-Barquero Journal: Schizophr Res Date: 2007-12-03 Impact factor: 4.939
Authors: Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan Journal: Can J Psychiatry Date: 2017-07-13 Impact factor: 4.356
Authors: Mark Turlington; Meredith J Noetzel; Aspen Chun; Ya Zhou; Rocco D Gogliotti; Elizabeth D Nguyen; Karen J Gregory; Paige N Vinson; Jerri M Rook; Kiran K Gogi; Zixiu Xiang; Thomas M Bridges; J Scott Daniels; Carrie Jones; Colleen M Niswender; Jens Meiler; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer Journal: J Med Chem Date: 2013-10-09 Impact factor: 7.446